靶向白细胞介素-23 治疗非感染性葡萄膜炎。
Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.
机构信息
Department of Ophthalmology, University of Washington, Seattle, Washington.
Casey Eye Institute, Oregon Health & Science University, Retinal and Vitreous Diseases/Surgery, Ocular Inflammation and Immunology, Portland, Oregon.
出版信息
Ophthalmology. 2018 Dec;125(12):1977-1983. doi: 10.1016/j.ophtha.2018.05.014. Epub 2018 Jul 4.
Abstract
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti-IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
摘要
白细胞介素 (IL)-23/IL-17 轴在免疫介导性疾病（如银屑病、银屑病关节炎、克罗恩病和葡萄膜炎）的发病机制中起着核心作用。因此，针对 IL-23/IL-17 轴已成为针对自身免疫性疾病患者药物开发的多个临床试验的焦点。我们简要描述了 IL-23/IL-17 轴的生物学特性及其与实验性和临床葡萄膜炎发病机制的相关性，并回顾了针对该途径的单克隆抗体治疗。最后，介绍了针对非感染性葡萄膜炎患者的抗 IL-23 生物疗法乌司奴单抗（STELARA，Janssen Biotech Inc，Horsham，PA）的 2 项正在进行的 2 期试验。
相似文献
1
Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.靶向白细胞介素-23 治疗非感染性葡萄膜炎。
Ophthalmology. 2018 Dec;125(12):1977-1983. doi: 10.1016/j.ophtha.2018.05.014. Epub 2018 Jul 4.
2
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.IL23/Th17通路作为慢性炎症性疾病的治疗靶点。
Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. doi: 10.2174/187152812800392805.
3
Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.Th17细胞在自身免疫性葡萄膜炎中的作用及抗IL-6治疗的效果
Rheumatology (Oxford). 2009 Apr;48(4):347-54. doi: 10.1093/rheumatology/ken489. Epub 2009 Jan 22.
4
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.炎症性肠病中靶向白细胞介素-23/白细胞介素-17轴生物疗法的安全性评估
Expert Opin Drug Saf. 2017 Jul;16(7):809-821. doi: 10.1080/14740338.2017.1338273. Epub 2017 Jun 9.
5
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.以白细胞介素-23/白细胞介素-17轴为靶点治疗银屑病和银屑病关节炎。
Expert Opin Biol Ther. 2015;15(12):1727-37. doi: 10.1517/14712598.2015.1084284. Epub 2015 Sep 7.
6
Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.乌司奴单抗治疗银屑病和银屑病关节炎：药物评价与文献复习。
Expert Opin Biol Ther. 2018 Jul;18(7):821-827. doi: 10.1080/14712598.2018.1492545. Epub 2018 Jul 9.
7
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.乌司奴单抗在银屑病免疫病理学中的作用，重点关注Th17-IL23轴：入门指南。
J Biomed Biotechnol. 2012;2012:147413. doi: 10.1155/2012/147413. Epub 2012 Jun 12.
8
Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.银屑病的生物治疗（第二部分）：靶向IL23/IL-17通路的新疗法的疗效与安全性
Curr Pharm Biotechnol. 2017;18(12):964-978. doi: 10.2174/1389201019666180103140643.
9
The safety of ustekinumab for the treatment of psoriatic arthritis.优特克单抗治疗银屑病关节炎的安全性。
Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9.
10
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.成功使用乌司奴单抗治疗非感染性葡萄膜炎，并伴有严重的银屑病关节炎和斑块型银屑病。
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12527. Epub 2017 Aug 18.
引用本文的文献
1
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.用于炎症性肠病的白细胞介素-23抑制剂：关键试验与实际考量
Curr Gastroenterol Rep. 2025 Jun 4;27(1):35. doi: 10.1007/s11894-025-00987-3.
2
Comparative Efficacy of Interleukin-7 and -15 Blockade in Alleviating Experimental Chronic Uveitis and Suppressing Pathogenic Memory CD4+ T Cells.白细胞介素-7和-15阻断在减轻实验性慢性葡萄膜炎及抑制致病性记忆CD4+ T细胞方面的比较疗效
Invest Ophthalmol Vis Sci. 2025 May 1;66(5):9. doi: 10.1167/iovs.66.5.9.
3
Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies.靶向生物制剂在眼科疾病治疗中的应用：当前及新兴疗法
Antibodies (Basel). 2024 Oct 11;13(4):86. doi: 10.3390/antib13040086.
4
TIGIT stimulation suppresses autoimmune uveitis by inhibiting Th17 cell infiltration.TIGIT 刺激通过抑制 Th17 细胞浸润来抑制自身免疫性葡萄膜炎。
J Leukoc Biol. 2024 Nov 4;116(5):1054-1060. doi: 10.1093/jleuko/qiae116.
5
Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances.贝赫切特葡萄膜炎的解码：发病机制和治疗进展的深入综述。
J Neuroinflammation. 2024 May 22;21(1):133. doi: 10.1186/s12974-024-03123-6.
6
Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.炎症性肠病的眼部表现：密切关注。
Cells. 2024 Jan 12;13(2):142. doi: 10.3390/cells13020142.
7
Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non-infectious uveitis.炎症细胞因子作为非感染性葡萄膜炎中视网膜内皮屏障功能障碍的介质
Clin Transl Immunology. 2023 Dec 12;12(12):e1479. doi: 10.1002/cti2.1479. eCollection 2023.
8
Behçet's Disease Uveitis.白塞病性葡萄膜炎
J Clin Med. 2023 May 24;12(11):3648. doi: 10.3390/jcm12113648.
9
Behçet uveitis: Current practice and future perspectives.白塞氏葡萄膜炎：当前实践与未来展望。
Front Med (Lausanne). 2022 Sep 7;9:968345. doi: 10.3389/fmed.2022.968345. eCollection 2022.
10
Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates.阿联酋银屑病关节炎的药物治疗管理、治疗监测和合并症管理共识声明。
Int J Rheum Dis. 2022 Oct;25(10):1107-1122. doi: 10.1111/1756-185X.14406. Epub 2022 Aug 2.
本文引用的文献
1
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).依奇珠单抗治疗活动性银屑病关节炎患者的疗效和安全性：一项 III 期研究（SPIRIT-P1）的 52 周结果。
J Rheumatol. 2018 Mar;45(3):367-377. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15.
2
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.成功使用乌司奴单抗治疗非感染性葡萄膜炎，并伴有严重的银屑病关节炎和斑块型银屑病。
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12527. Epub 2017 Aug 18.
3
Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.针对中重度银屑病的新型生物制剂靶向白细胞介素-23 和白细胞介素-17。
Clin Drug Investig. 2017 Oct;37(10):891-899. doi: 10.1007/s40261-017-0550-z.
4
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).用布罗达单抗治疗的中重度银屑病患者起效迅速：来自两项3期随机临床试验（AMAGINE-2和AMAGINE-3）数据的汇总分析。
J Am Acad Dermatol. 2017 Aug;77(2):372-374. doi: 10.1016/j.jaad.2017.03.026.
5
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.古塞库单抗治疗乌司奴单抗应答不足的银屑病患者的疗效和安全性：随机、双盲、III 期 NAVIGATE 试验结果。
Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.
6
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.替西单抗与安慰剂或依那西普治疗慢性斑块型银屑病（reSURFACE 1 和 reSURFACE 2）：两项随机对照、3 期临床试验的结果。
Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6.
7
The association between genetic polymorphisms of the interleukin-23 receptor gene and susceptibility to uveitis: a meta-analysis.白细胞介素-23受体基因的遗传多态性与葡萄膜炎易感性之间的关联：一项荟萃分析。
BMC Ophthalmol. 2017 May 30;17(1):81. doi: 10.1186/s12886-017-0477-4.
8
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.依奇珠单抗治疗肿瘤坏死因子抑制剂应答不足的活动性银屑病关节炎患者：SPIRIT-P2 期 3 期临床试验 24 周随机、双盲、安慰剂对照期间的结果。
Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.
9
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.利纳西珠单抗与乌司奴单抗治疗中重度斑块状银屑病的疗效比较。
N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.
10
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.在中重度克罗恩病患者中使用选择性白细胞介素-23 抑制剂 risankizumab 进行诱导治疗：一项随机、双盲、安慰剂对照的 2 期研究。
Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12.
Zotero 插件